These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24881765)

  • 1. Are we done monkeying around with TRIM5α?
    Campbell E
    Mol Ther; 2014 Jun; 22(6):1072-1073. PubMed ID: 24881765
    [No Abstract]   [Full Text] [Related]  

  • 2. Stabilized human TRIM5α protects human T cells from HIV-1 infection.
    Richardson MW; Guo L; Xin F; Yang X; Riley JL
    Mol Ther; 2014 Jun; 22(6):1084-1095. PubMed ID: 24662946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of novel TRIM5alpha variants, Gly110Arg and G176del, on the anti-HIV-1 activity and the susceptibility to HIV-1 infection.
    Nakajima T; Nakayama EE; Kaur G; Terunuma H; Mimaya JI; Ohtani H; Mehra N; Shioda T; Kimura A
    AIDS; 2009 Oct; 23(16):2091-100. PubMed ID: 19710594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In defense of the cell: TRIM5alpha interception of mammalian retroviruses.
    Lee K; KewalRamani VN
    Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10496-7. PubMed ID: 15252204
    [No Abstract]   [Full Text] [Related]  

  • 5. TRIM5α and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment.
    Singh R; Patel V; Mureithi MW; Naranbhai V; Ramsuran D; Tulsi S; Hiramen K; Werner L; Mlisana K; Altfeld M; Luban J; Kasprowicz V; Dheda K; Abdool Karim SS; Ndung'u T
    J Virol; 2014 Apr; 88(8):4291-303. PubMed ID: 24478420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression analysis of LEDGF/p75, APOBEC3G, TRIM5alpha, and tetherin in a Senegalese cohort of HIV-1-exposed seronegative individuals.
    Mous K; Jennes W; Camara M; Seydi M; Daneau G; Mboup S; Kestens L; Van Ostade X
    PLoS One; 2012; 7(3):e33934. PubMed ID: 22479480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry.
    Chatterji U; Bobardt MD; Gaskill P; Sheeter D; Fox H; Gallay PA
    J Biol Chem; 2006 Dec; 281(48):37025-33. PubMed ID: 17028189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caging the beast: TRIM5α binding to the HIV-1 core.
    Diaz-Griffero F
    Viruses; 2011 May; 3(5):423-8. PubMed ID: 21994740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique features of TRIM5alpha among closely related human TRIM family members.
    Li X; Gold B; O'hUigin C; Diaz-Griffero F; Song B; Si Z; Li Y; Yuan W; Stremlau M; Mische C; Javanbakht H; Scally M; Winkler C; Dean M; Sodroski J
    Virology; 2007 Apr; 360(2):419-33. PubMed ID: 17156811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defects in assembly explain reduced antiviral activity of the G249D polymorphism in human TRIM5α.
    Kömürlü S; Bradley M; Smolin N; Imam S; Pauszek RF; Robia SL; Millar D; Nakayama EE; Shioda T; Campbell EM
    PLoS One; 2019; 14(3):e0212888. PubMed ID: 30889178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort.
    Price H; Lacap P; Tuff J; Wachihi C; Kimani J; Ball TB; Luo M; Plummer FA
    AIDS; 2010 Jul; 24(12):1813-21. PubMed ID: 20588169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional evidence for the involvement of microtubules and dynein motor complexes in TRIM5α-mediated restriction of retroviruses.
    Pawlica P; Le Sage V; Poccardi N; Tremblay MJ; Mouland AJ; Berthoux L
    J Virol; 2014 May; 88(10):5661-76. PubMed ID: 24600008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection.
    van Manen D; Rits MA; Beugeling C; van Dort K; Schuitemaker H; Kootstra NA
    PLoS Pathog; 2008 Feb; 4(2):e18. PubMed ID: 18248091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic body component TRIM5{alpha} requires lipid-enriched microdomains for efficient HIV-1 restriction.
    Ohmine S; Sakuma R; Sakuma T; Thatava T; Solis GP; Ikeda Y
    J Biol Chem; 2010 Nov; 285(45):34508-17. PubMed ID: 20810659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of TRIM5α in vivo.
    Nakayama EE; Shioda T
    AIDS; 2015 Sep; 29(14):1733-43. PubMed ID: 26372380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIM5α associates with proteasomal subunits in cells while in complex with HIV-1 virions.
    Lukic Z; Hausmann S; Sebastian S; Rucci J; Sastri J; Robia SL; Luban J; Campbell EM
    Retrovirology; 2011 Nov; 8():93. PubMed ID: 22078707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasomal degradation of TRIM5alpha during retrovirus restriction.
    Rold CJ; Aiken C
    PLoS Pathog; 2008 May; 4(5):e1000074. PubMed ID: 18497858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity.
    Battivelli E; Migraine J; Lecossier D; Yeni P; Clavel F; Hance AJ
    J Virol; 2011 Nov; 85(22):11846-54. PubMed ID: 21917976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using TRIM5α as an HIV therapeutic: the alpha gene?
    Anderson JS
    Expert Opin Biol Ther; 2013 Jul; 13(7):1029-38. PubMed ID: 23480791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1.
    Chan E; Towers GJ; Qasim W
    Viruses; 2014 Jan; 6(1):243-63. PubMed ID: 24424502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.